---
title: "Altamira Therapeutics to Host First Half 2025 Financial Results and Business Update Call on August 29, 2025"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254682949.md"
description: "Altamira Therapeutics Ltd. will host its Half Year 2025 Financial Results and Business Update Call on August 29, 2025, at 8:00 am ET. CEO Thomas Meyer and COO Covadonga Pañeda will present. The call will be in listen-only mode, with a replay available afterward. Altamira focuses on RNA delivery technology and has two siRNA programs in preclinical development. The company also holds a stake in Altamira Medica AG and is exploring partnerships for its inner ear assets."
datetime: "2025-08-26T20:00:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254682949.md)
  - [en](https://longbridge.com/en/news/254682949.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254682949.md)
generator: "portal-rs"
---

# Altamira Therapeutics to Host First Half 2025 Financial Results and Business Update Call on August 29, 2025

HAMILTON, BERMUDA / ACCESS Newswire / August 26, 2025 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it will host its Half Year 2025 Financial Results and Business Update Call on Friday, August 29, 2025. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks.

**Event**: Altamira Therapeutics First Half 2025 Financial Results and Business Update Call

**Date**: Friday, August 29, 2025

**Time**: 8:00 am ET

**Access:**

**Toll Free:** 888-506-0062

**International:** 973-528-0011

**Participant Access Code:** 427043

**Webcast URL:** https://www.webcaster4.com/Webcast/Page/2797/52765

Participants will be greeted by an operator and asked for the access code. If a caller does not have the code, they can reference the company name.

The call will be in listen-only mode.

A replay of the call will be available 30 minutes after the live event via the Investors section of the Altamira website at https://ir.altamiratherapeutics.com/.

**Replay access:**

Toll Free: 877-481-4010

International: 919-882-2331

Replay Passcode: 52765

Expiration: Friday, September 12, 2025

**About Altamira Therapeutics**

Altamira Therapeutics (OTCQB:CYTOF) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (xPhore™ platform). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a 49% stake (with additional economic rights) in Altamira Medica AG, which holds its commercial-stage legacy asset Bentrio®, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets. Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com/

**Investor Contact**

Hear@altamiratherapeutics.com

**SOURCE:** Altamira Therapeutics

View the original press release on ACCESS Newswire

### Related Stocks

- [CYTOF.US](https://longbridge.com/en/quote/CYTOF.US.md)

## Related News & Research

- [Why is your gold waiting on a speech?](https://longbridge.com/en/news/296733808.md)
- [There’s More to Consider, Says Investor About Sandisk Stock](https://longbridge.com/en/news/296795615.md)
- [AMD or Nvidia: Load Up on One AI Chip Stock, but Avoid the Other, Says Investor](https://longbridge.com/en/news/296792383.md)
- [Michael Burry Says He 'Flipped' His Alibaba Stock into JD and Won't Be Flipping Back — Hong Kong-Listed Stock Falls Nearly 10% on $10B Raise](https://longbridge.com/en/news/296735167.md)
- [Balanced Risk/Reward Keeps Workday at Hold as Brent Thill Raises Price Target from $205 to $225 on Potential Silver Lake Takeout Upside](https://longbridge.com/en/news/296711228.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**